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it has been more than 50 years since thalidomide was withdrawn from the world market due to its 
teratogenic potential. However, its widespread use around the world resumed due to its immunomo-
dulatory and anti-angiogenic properties. the drug established itself in new therapies, and interest 
continued with the emergence of more potent analogs, the most notable being lenalidomide and 
pomalidomide, which are not approved in Brazil. the question that arises after analog synthesis is: 
Do these drugs also have the same teratogenic potential? the answer to this question is based only 
on experimental studies because exposure to humans is not authorized and has not yet been descri-
bed. Although thalidomide has been recognized as a powerful human teratogen for many years, its 
molecular mechanisms of teratogenesis remain to be fully explained. Efforts with animal models and 
human genetic studies have clarified some important pathways that are most likely involved in the 
teratogenic action of thalidomide. However, it has not yet been possible to identify the teratogenic 
domain of the molecule from the therapeutic ones. Moreover, there are species-specific differences 
that must be taken into consideration when teratogenicity is evaluated.
KEYWOrDS: thalidomide; Lenalidomide; Pomalidomide; teratogenesis; thalidomide 
Syndrome; iNageMP
rESuMO
Faz mais de 50 anos que a talidomida foi retirada do mercado mundial devido ao seu 
potencial teratogênico. Entretanto, seu uso disseminado em todo o mundo foi retomado 
devido às suas propriedades imunomodulatórias e antiangiogênicas. A droga foi utilizada 
em novas terapias e o interesse continuou com a emergência de análogos mais potentes, 
os mais notáveis deles sendo a lenalidomida e a pomalidomida, que não estão aprovados 
no Brasil. A questão que surge após a síntese dos análogos é: Estas drogas também têm o 
mesmo potencial teratogênico? A resposta a esta pergunta baseia-se apenas em estudos 
experimentais, pois a exposição a humanos não está autorizada e ainda não foi reporta-
da. Embora a talidomida tenha sido durante muitos anos reconhecida como um poderoso 
teratógeno humano, os mecanismos moleculares da teratogênese ainda não foram com-
pletamente explicados. os esforços com modelos animais e estudos genéticos humanos 
para entender o efeito tóxico da droga esclareceram alguns importantes caminhos que 
estão muito provavelmente envolvidos na ação teratogênica. Entretanto, ainda não foi 
possível isolar o agente teratogênico das outras ações terapêuticas na talidomida e seus 
análogos. Além disso, há diferenças específicas da espécie que devem ser levadas em 
consideração quando a teratogenicidade é avaliada.
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Thalidomide: A controversial Drug
Thalidomide (α-[N-phthalimido]-glutarimide) was synthe-
sized in 1954 in West germany by the german company Chemie 
Grünenthal. The first trials revealed that it had a depressant 
effect on the central nervous system (CNS) and induced sleep; 
therefore, it was indicated primarily as a sedative agent1,2. 
in 1956, thalidomide was introduced into the market as a se-
dative, as well as for several other indications, such as the tre-
atment of irritability, poor concentration, anxiety, insomnia, 
nausea, hyperthyroidism, and infectious diseases2,3.
After this, thalidomide quickly came to be manufactured 
and sold worldwide under more than 40 trade names and rea-
ched extraordinary levels of sales — about 15 tons in germany 
in 19614.
toxicity studies in rodents had shown that thalidomide 
was a drug with a low risk of toxicity and few side effects5. 
the observed toxicity was so low that it was not possible to 
determine the lethal dose (LD50) in animals. Additionally, sui-
cide attempts with the drug were unsuccessful due to organic 
sequelae1,3.
However, starting in 1959, there were a large num-
ber of reports of newborns with birth defects, initially in 
germany2. the clinical status of these children was mainly cha-
racterized by defects in the development of the long bones (in 
which hands and feet varied between normal and rudimentary) 
associated with other malformations6. it was only at the end of 
1961, with an increasing number of cases, that Lenz suggested 
a possible correlation between birth defects and the use of tha-
lidomide during pregnancy7,8. in Australia, McBride also mentio-
ned an increase in these birth defects and correlated it with the 
use of this drug9.
the suspension of the sale of thalidomide in germany and 
England occurred in 1961, and subsequently in several other 
countries3. in August 1962, it was already possible to observe a 
significant decline in the number of limb malformations1, thus 
confirming the causal relationship between thalidomide use 
during pregnancy and the increase in the prevalence of the-
se malformations. Even so, thousands of children had already 
been born with such anomalies — the estimated number was 
10,000 children born around the world, and the number of mis-
carriages as a result of using the drug is unknown10,11.
in the same decade, thalidomide was already being used 
for the treatment of an inflammatory reaction from leprosy. 
in 1965, the israeli dermatologist Jacob Sheskin prescribed 
thalidomide as a sedative and analgesic for six patients with 
erythema nodosum leprosum (ENL), an immune condition 
resulting from infection caused by Mycobacterium leprae 
and characterized by hot, painful, mobile skin lesions, ei-
ther associated or unassociated with a systemic condition of 
fever, malaise, arthralgia, myalgia, and other symptoms12,13.
Besides being a great sedative, the clinical signs and symptoms 
were dramatically reduced within 48 hours. thereafter, con-
trolled placebo studies showed that thalidomide was responsi-
ble for the clinical improvement of the patients14,15.
undesirable Effects of Thalidomide
Due to the large amount of epidemiological data available 
in the 1960s, it was possible to determine the period of the 
gestation that is sensitive to the teratogenic action of thali-
domide. the teratogenic window was established as being be-
tween the 34th and 50th day after the last menstrual period or 
20 to 36 days after fertilization16. Within this period, it is also 
possible to make a correlation between the days of ingesting 
the drug and the observed malformations.
it is believed that between 10% and 50% of women who in-
gest thalidomide during this period of sensitivity have children 
affected by the embryopathy16, making this drug a potent tera-
togen for humans with small doses of thalidomide (between 50 
and 100 mg) capable of producing typical defects1.
Limb malformations are most frequently described among 
all the malformations produced by the teratogenic effects 
of thalidomide. the defects are bilateral but not necessarily 
symmetrical, and opposite limbs are affected unequally. it 
is possible to divide the limb defects into four groups1,6,16,17:
• Phocomelia (short or rudimentary limbs) in all four
limbs;
• Phocomelia or amelia (total absence) of upper limbs,
with other defects in the lower limbs;
• Phocomelia or amelia in upper limbs, with normal lo-
wer limbs;
• Defects in predominant lower limbs (femoral hypo-
plasia or phocomelia of lower extremities), usually
associated with curved upper limbs or other defects.
the lower and upper limbs have pre-axial and intercala-
ry alterations, with the upper extremities usually affected by 
loss of fingers, and the lower extremities by polydactyly and 
syndactyly6,16.
the limb defects also include aplasia of the thenar muscle, 
thumbs with three phalanges absent or hypoplastic, absence of 
phalanges, hypoplasia of the radius and ulna, and hypoplasia of 
shoulders and hips, among other malformations1,16.
the limb defects may be associated with abnormali-
ties in other organs, and virtually every organ of the body 
can be affected6. Malformations and/or hearing loss are very 
common, with microtia and anotia the most frequent16,17. 
ocular abnormalities such as coloboma, microphthalmia, and 
anophthalmia, are commonly found4,18. the most common neu-
rological abnormalities are deafness and facial paralysis; ho-
wever, some studies have reported mental retardation in 6.6% 
of affected individuals4. Hemangioma in the midline of the 
face and lip and/or cleft palate is more frequent for victims 
of thalidomide than for the general population2. Among the 
abnormalities in internal organs, abnormalities of the larynx, 
trachea, and lung lobulation are frequent16. Cardiac malforma-
tions, including ventricular septal defects, aortic coarctation, 
and tetralogy of Fallot, occur with considerable frequency, and 
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Estimates of the mortality rate among victims of thalidomi-
de indicate rates of between 40% and 45%1, with most of them 
due to heart, kidney, and gastrointestinal anomalies, which are 
less common among survivors due to their severities2.
resurgence and establishment of thalidomide
in the 1990s, the mechanism of action involved in impro-
ving ENL symptoms was mainly attributed to the degradation 
of high levels of tumor necrosis factor alpha (TNF-α)13,19. 
in 1991, Sampaio et al. found that thalidomide was able to 
decrease the level of TNF-α released by monocytes and ma-
crophages stimulated by endotoxin through the degradation of 
its in vitro messenger RNA (mRNA)19,20.
Besides the immunomodulatory and anti-inflammatory 
effects, thalidomide also inhibits the development of new 
blood vessels21. Independent of activating interleukin (IL)-2 
(which possesses anti-tumor activity) and decreasing IL-6 (a 
potent growth factor for malignant plasma cells)22, the an-
giogenetic inhibition mechanism for thalidomide appears to 
involve blocking growth factors21.
D’Amato et al21. showed that intraperitoneal administra-
tion of thalidomide inhibits cornea neovascularization in rab-
bits and mice by blocking vascular endothelial growth factor 
(VEGF) and basic fibroblast growth factor (bFGF)21,23 — the 
latter also occurs following oral administration. When the 
enantiomers of thalidomide are analyzed separately, the levo-
gyrous configuration shows greater inhibition of angiogenesis 
compared to the other isoform, which may be an indication 
that the anti-angiogenic and teratogenic properties of the 
drug are strongly correlated29.
The recognition of these anti-inflammatory, immunomodu-
latory, and anti-angiogenic properties has created opportunities 
for studies both with thalidomide and therapeutic targets in se-
veral clinical conditions that involve both TNF-α and angiogene-
sis-dependent factors. The result is that thalidomide is the first 
choice in many countries, including Brazil, for the treatment 
of ENL and multiple myeloma, and it is part of the treatment 
for several other conditions, such as lupus, graft-versus-host 
disease, and AiDS-related idiopathic ulcers4,10,24,25.
Thalidomide Analogs
At the same time that thalidomide was restoring its place 
and approval for use on the world stage, there was interest in 
the synthesis of analogs with higher therapeutic potency and 
reduced side effects. these side effects, especially the tera-
togenicity and peripheral neuropathy, are the limiting factors 
of treatment.
the most well known thalidomide analogs are lenali-
domide (CC-5013)26 and pomalidomide (CC-4047)27. these 
drugs were approved in the United States in 2006 and 2013, 
respectively, to treat multiple myeloma, and they have a 
subtle change in the phthalimido moiety of the original 
molecule. this subtle variation gives the analogs (at least 
for in vitro use) greater potency in inhibiting TNF-α and a 
greater ability to co-stimulate t cells, as well as less detri-
mental side effects28,29.
in Brazil, thalidomide is cheaply manufactured by the 
Fundação Ezequiel Dias (FUNED, a pharmaceutical arm of the 
government), which has proven to be very cost-effective. If 
analogs were to enter Brazil, they would not have the same 
cost-effectiveness due to the royalties30.
thus, a new class of drugs called immunomodulatory dru-
gs (IMiDs) has arisen; for example, thalidomide, lenalidomide, 
and pomalidomide. the term “iMiDs” refers to the iMiD licensed 
by the Celgene Corporation (Summit, NJ) for the treatment of 
various inflammatory and neoplastic diseases. The IMiDs were 
originally defined by their ability to inhibit TNF-α and further 
stratified by their relative effects on other cytokines32.
iMiDs have several action mechanisms in common; for 
example, suppressing TNF-α, co-stimulation of T-cells, incre-
ased effector function of natural killer cells, VEgF expression, 
suppression of cyclooxygenase (COX-2) expression, etc29,31,32. 
At the same time, they have different profiles for toxic effects; 
for example, constipation, peripheral neuropathy, neutropeny, 
thromboembotic events, and secondary malignancies26,27.
Teratogenesis of Thalidomide Analogs
Studies assessing the teratogenicity of the analogs are 
still very limited in animals, and no human experience has 
been recorded. in 2007, Christian et al.33 demonstrated that, 
in therapeutic doses, lenalidomide is not teratogenic in rab-
bits, which is one of the animal models for thalidomide tera-
togenicity. However, it was observed that at maternally toxic 
doses, lenalidomide produced developmental delays, low 
birth weight, and miscarriages, but no typical malformations 
were observed33. This finding was not confirmed in primates, 
in which there was a malformation pattern consistent with 
thalidomide embryopathy26.
the effects that are toxic to the embryo are also contra-
dictory in the experiments with pomalidomide. in vitro and 
in vivo assays performed by Mahoni et al.34 with zebrafish and 
chickens showed that lenalidomide, but not pomalidomide, 
was teratogenic. Besides this, the toxicity profile of poma-
lidomide was lower when compared with its counterparts, 
even in doses that achieved an anti-inflammatory response34. 
However, data published by the manufacturer showed that 
pomalidomide is teratogenic in rats and rabbits, which inclu-
des limb and cardiac malformations compatible with thalido-
mide teratogenicity27.
these discrepant results demonstrate the need for serial 
evaluation in different experimental models and at different 
doses to reach a consensus regarding the teratogenicity of 
thalidomide analogs. Because we are dealing with a molecule 
derived from a potent teratogen, its use during pregnancy and 
use by women of childbearing age is considered to be totally 
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Teratogenic Molecular Mechanisms of 
Thalidomide and its Analogs
the study of the teratogenic mechanisms of the iMiDs at-
tempts to identify what the causes of the molecular terato-
genesis are so that the moiety can be isolated and to obtain 
a safe medication. These targets remain to be identified, but 
many advances have been made in this area in recent decades, 
especially with thalidomide.
The hypotheses with greater scientific reliability are those 
tested in well-established animal models (rabbits, chickens, and 
zebrafish) and based on three main phenomena: the formation 
of reactive oxygen species (ROS), anti-angiogenic mechanisms, 
and binding to the cereblon protein (CRBN)21,35-42.
Parman et al.35 showed that thalidomide induces oxidation 
in the DNA of rabbit embryos exposed in utero to thalidomide, 
and that this is one of the indications that the formation of roS 
and oxidative stress are involved in the process. in this study, 
oxidation did not occur in mouse embryos, which are resistant 
to thalidomide teratogenesis, and this could be one reason for 
the resistance and species-specific teratogenicity. In agreement 
with this is the hypothesis that roS formation would reduce the 
capacity of the nuclear factor kappa beta (NF-KB) — a redox-sen-
sitive transcription factor and growth regulator of the limbs — to 
bind to the promoter of its target genes, thereby decreasing their 
expression. Examples of genes regulated by NF-KB are fibroblast 
growth factor 10 (FGF10), msh homeobox 1 (MSX1), Twist, sonic 
hedgehog (SHH), and others that are essential for limb growth. 
Decreased expression of these genes causes a disturbance in the 
regulation of feedback with other genes; for example, suppres-
sion of FgF8 expression and overexpression of bone morphogene-
tic protein 4 (BMP4) compromises near-distal limb growth, which 
is expressed as phocomelia and amelia36.
other studies with animal models have also provided 
strong evidence supporting the anti-angiogenic role in the te-
ratogenesis of thalidomide21,37,38. Blood vessels are a primary 
target of thalidomide teratogenesis, and events such as the 
loss of FgF8 and FgF10 signaling are secondary to the effects 
on the affected vessels42.
ito et al.40 demonstrated that the CrBN protein interacts 
directly or indirectly with thalidomide and indirectly with the 
damage-specific DNA binding protein 1 (DDB1). Both are part of 
an E3 ubiquitin ligase complex together with the cullin 4A pro-
tein (CUL4A). They assert that the binding of thalidomide in CRBN 
would decrease the CrBN ubiquitination activity in the E3 ubiqui-
tin ligase complex, and that the increase of the non-ubiquitinated 
substrates would cause an imbalance in the expression of some 
genes, such as FgF8, FgF10, and BMP4, etc39-41.
the fact that this protein is the primary target for binding 
to thalidomide has generated important developments regar-
ding the action mechanisms of thalidomide and its analogs. For 
example, the loss of CrBN expression is associated with resis-
tance to the multiple myeloma treatment during treatment 
with pomalidomide, and this has been evaluated as a possi-
ble biomarker response to treatment of multiple myeloma32,43. 
Human studies attempting to identify the teratogenic molecu-
lar mechanisms are based on genetic studies that seek to iden-
tify susceptibility factors in people affected by the syndrome. 
in a comparison of unaffected people with people who have 
thalidomide embryopathy, Vianna et al.44 identified many more 
genetic variants related to the reduced enzyme expression of 
the endothelial nitric oxide synthase gene (eNOS or NOS3). In 
a published abstract, the same group identified the presence 
of rare variants in the gene region that encodes the binding 
moiety between thalidomide and CrBN45. Although the results 
were not statistically significant, these rare variants should be 
studied further because they may be able to clarify individual 
response mechanisms for drug exposure.
In general, the findings in humans suggest that while not 
recognizing the real genetic contribution to the occurrence of 
thalidomide embryopathy, rare variants in the CrBN gene, as 
well as polymorphisms in NoS3, seem to have an important 
role and should be studied further. Additionally, other genes 
encoding proteins involved in oxidative stress, angiogenesis, 
and ubiquitin E3 ligase complex, may clarify other important 
issues, such as species-specific mechanisms, tissue specificity, 
and phenotypic differences.
Thalidomide cases in brazil Explain the Fear 
Surrounding the Introduction of an Analog
The first cases of malformations associated with the use 
of thalidomide-based drugs in Brazil were reported in 1960; 
however, cases were subsequently recorded for the year 1959. 
The official number in Brazil until 1965 is about 300 cases; 
however, some cases were difficult to prove due to the high 
incidence of self-medication and the time elapsed from drug 
ingestion until diagnosis2,3,11.
through 204 records from the Brazilian Association of tha-
lidomide Victims (ABVT), Schmidt and Salzano46 evaluated 93 
patients with thalidomide embryopathy who were born between 
1959 and 1963. in this study, it was possible to establish epi-
demiological data, which revealed a greater concentration of 
births in the states of Rio Grande do Sul (RS), Minas Gerais (MG), 
and São Paulo (SP) and a greater number of births in 196246.
Despite the recognition of cases occurring from 1970 to 
1990 by non-governmental organizations, such as the Move-
ment for the reintegration of People Affected by Leprosy 
(MORHAN) and the Brazilian Association of Thalidomide Syn-
drome Sufferers (ABPST), the only manifestations published 
in the scientific literature were from Gollop and Eigier47 and 
Castilla et al.48 gollop and Eigier47 prenatally diagnosed, for 
the first time, a case of thalidomide embryopathy in a fetus 
whose mother was in treatment for ENL with daily doses of 100 
mg taken up to the 35th day of gestation. Pregnancy was inter-
rupted by parental decision because the fetus showed phoco-
melia in all four limbs47. Castilla et al.48 reported 34 cases of 
thalidomide embryopathy in South America between 1969 and 
1995, and of these, 33 cases were from Brazil — 1 was in 1969, 
6 during the 1970s, 20 in the 1980s, and 6 in the 1990s. these 
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gion having the highest occurrence rate48. the authors attribu-
ted the high incidence of a second generation of victims to the 
high prevalence of leprosy in Brazil, and also due to the drug’s 
lax control measures.
Despite the restrictions imposed on thalidomide use after the 
international scandal, which involved Brazilian victims between 
1970 and 1990, and the apparent control and monitoring of thali-
domide embryopathy (mainly due to Law 10651/2003 which regu-
lates the use of thalidomide)25, in the years 2005 and 2006, new 
cases of thalidomide embryopathy have been reported. these 
cases come to the attention of the teratogen information Service 
(SIAT) of Porto Alegre in a totally random manner, without any 
notification or registration on the part of the competent health 
authorities or the inspection services related to the drug49.
These three cases occurred in the states of Maranhão (MA), 
Rondônia (RO), and Rio Grande do Sul (RS). The recommen-
dation to use thalidomide was for the treatment of ENL (two 
cases) and multiple myeloma (one case). In two cases, the 
mothers of the malformed babies were undergoing treatment 
with thalidomide, but they were using it at their own discre-
tion through a close relative with a prescription — a very com-
mon habit in our population49.
the emergence of these new cases suggests the need for sur-
veillance to evaluate the real occurrence of new cases in Brazil. 
in 2011, a study was published that established a surveillance 
tool based on the typical congenital defects of this embryopa-
thy — known as the thalidomide embryopathy phenotype (TEP). 
It identified two cases compatible with the syndrome. Although 
there was no proof of the medication being used by the mothers, 
the tool was shown to be sensitive and effective for its purpose. 
Besides this, tEP frequencies have been statistically higher in re-
cent years, coinciding with the period of increased availability of 
thalidomide due to the expansion of its uses50.
During this surveillance, two more cases of embryopathy 
were registered in 2010 in the interior of the state of Mara-
nhão, where there is a high prevalence of leprosy. the disco-
very of the first case led to the identification of the second due 
to the typical characteristics of the syndrome17. From these 
notifications, new rules for the use and prescription of thalido-
mide came into force (Resolution RDC no. 11, March 2011) with 
more restrictive characteristics for the use and dispensation of 
the drug in Brazil51.
conclusions
Even with stricter surveillance and regulations, the case 
history makes Brazil reticent to introduce a thalidomide ana-
log. Using a new iMiD for restricted conditions is a possibility to 
be discussed; however, we agree with Paumgartten30 that this 
should occur only in cases in which the clinical superiority is 
demonstrated by clinical trials. Besides this, the easy adminis-
tration (orally) and the sharing of medications (a practice that 
is still quite common and which has been observed in the latest 
cases of the syndrome) cannot be overlooked in making this de-
cision, because teratogenicity in humans for this class of drugs 
cannot be eliminated.
thus, the caution of waiting for larger and improved ex-
periences with the use of a new drug can be considered to be 
a watershed — the case of thalidomide in the United States 
reinforces this idea. in dealing with thalidomide in Brazil, this 
caution is enhanced due to the history marked by the preca-
rious surveillance and continuous recording of cases of thali-
domide embryopathy.
thalidomide analogs are used outside Brazil primarily for 
cancer treatment. With the approval of an analog, there will 
probably be efforts to test these molecules under other condi-
tions, particularly in ENL, which is still very common in Brazil. 
thus, one would not be able to guarantee that this medication 
is totally out of the teratogenic range and that the first in ute-
ro exposure of second-generation iMiDs would occur in Brazil.
the notion that thalidomide analogs are, from a clinical 
point of view, generally more potent than the parent com-
pound, can be seen as a simplified way to understand and ex-
plain the action mechanisms and the biological function of the 
iMiDs, especially in relation to the teratogenicity in animals 
compared with humans. the study of the molecular targets of 
thalidomide and its analogs, both for their therapeutic action 
and ability to induce malformations, should help to understand 
this intriguing phenomenon of teratogenesis and assist in the 
development of safer compounds.
Meanwhile, because the drug has so many features that 
can benefit people with various debilitating conditions, it is 
necessary to implement new prevention approaches that seek 
to effectively control the drug and ensure its safe and ratio-
nal use.
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